Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade–refractory idiopathic multicentric Castleman disease

Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease

(2019) Christopher S. Nabel et al.   PLoS One

Plasma proteomics identifies a ‘chemokine storm’ in idiopathic multicentric Castleman disease

(2018) Sheila K. Pierson et al.   AMERICAN JOURNAL OF HEMATOLOGY

Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial

(2018) Zhi-Wei Lai et al.   LANCET

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

(2018) Frits van Rhee et al.   BLOOD

Elevated serum interferon γ-induced protein 10 kDa is associated with TAFRO syndrome

(2017) Noriko Iwaki et al.   Scientific Reports

Hyperactive mTOR pathway promotes lymphoproliferation and abnormal differentiation in autoimmune lymphoproliferative syndrome

(2016) S. Volkl et al.   BLOOD

Sirolimus-Based Immunosuppressive Regimens in Renal Transplantation: A Systemic Review

(2016) D.Q. Zhao et al.   TRANSPLANTATION PROCEEDINGS

Idiopathic multicentric Castleman's disease: a systematic literature review

(2016) Amy Y Liu et al.   Lancet Haematology

mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging

(2015) Andras Perl   Annals of the New York Academy of Sciences

Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease

(2015) C. Casper et al.   CLINICAL CANCER RESEARCH

Mechanistic Target of Rapamycin Complex 1/S6 Kinase 1 Signals Influence T Cell Activation Independently of Ribosomal Protein S6 Phosphorylation

(2015) Robert J. Salmond et al.   JOURNAL OF IMMUNOLOGY

Multiplexed protein profiling after aneurysmal subarachnoid hemorrhage: Characterization of differential expression patterns in cerebral vasospasm

(2014) Brian P. Walcott et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial

(2014) Frits van Rhee et al.   LANCET ONCOLOGY

Use of a claims database to characterize and estimate the incidence rate for Castleman disease

(2014) Nikhil Munshi et al.   LEUKEMIA & LYMPHOMA

Causal analysis approaches in Ingenuity Pathway Analysis

(2013) Andreas Krämer et al.   BIOINFORMATICS

Increased CD38 expression in T cells and circulating anti-CD38 IgG autoantibodies differentially correlate with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients

(2013) Esther J. Pavón et al.   CYTOKINE

Eruptive Cherry Hemangiomatosis Associated With Multicentric Castleman Disease

(2013) David Fajgenbaum et al.   JAMA Dermatology

The clinical spectrum of Castleman's disease

(2012) Angela Dispenzieri et al.   AMERICAN JOURNAL OF HEMATOLOGY

Rapamycin Inhibits Proliferation of Hemangioma Endothelial Cells by Reducing HIF-1-Dependent Expression of VEGF

(2012) Damian Medici et al.   PLoS One

Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks

(2011) Brian Magnuson et al.   BIOCHEMICAL JOURNAL

Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis

(2011) Francis X. McCormack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery

(2011) Larry Gold et al.   PLoS One

Siltuximab, a Novel Anti–Interleukin-6 Monoclonal Antibody, for Castleman's Disease

(2010) Frits van Rhee et al.   JOURNAL OF CLINICAL ONCOLOGY

Rapamycin Inhibits VEGF-Induced Microvascular HyperpermeabilityIn Vivo

(2010) DAVID D. KIM et al.   MICROCIRCULATION

Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome

(2009) David T. Teachey et al.   BRITISH JOURNAL OF HAEMATOLOGY

Antitumoral Activity of Rapamycin Mediated Through Inhibition of HIF-1alpha and VEGF in Hepatocellular Carcinoma

(2008) Wei Wang et al.   DIGESTIVE DISEASES AND SCIENCES